BioMarin's Roctavian struggles continue. Is a divestment in the future?
Less than a year into a rocky rollout for its gene therapy Roctavian, BioMarin is now talking about whether the product might be a better …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
